Rachel E Salas1, Charlene E Gamaldo, Richard P Allen. 1. Department of Neurology, Division of Pulmonary/Critical Care, Johns Hopkins School of Medicine, Baltimore, Maryland 21287, USA. rsalas3@jhmi.edu
Abstract
PURPOSE OF REVIEW: Although restless legs syndrome (RLS) is a disorder recognized in the medical literature since the 17th century, there have only recently been significant clinical and scientific advances in diagnosis, epidemiology and understanding the disorder, mainly due to the advent of dopaminergic treatment. RECENT FINDINGS: Recent discoveries have uncovered the iron-dopamine connection in RLS and the basic dopaminergic pathology related to the RLS symptoms. These have led to new understanding of the morbidity of RLS and the many conditions associated with RLS, which have also supported new approaches to treatment. These developments are each briefly described here. SUMMARY: Although there has been progress in understanding, diagnosing and treating RLS, it remains an underdiagnosed and undertreated condition severely impairing functioning of patients with moderate-to-severe disease. Much work is needed to improve on current, as well as other novel therapies.
PURPOSE OF REVIEW: Although restless legs syndrome (RLS) is a disorder recognized in the medical literature since the 17th century, there have only recently been significant clinical and scientific advances in diagnosis, epidemiology and understanding the disorder, mainly due to the advent of dopaminergic treatment. RECENT FINDINGS: Recent discoveries have uncovered the iron-dopamine connection in RLS and the basic dopaminergic pathology related to the RLS symptoms. These have led to new understanding of the morbidity of RLS and the many conditions associated with RLS, which have also supported new approaches to treatment. These developments are each briefly described here. SUMMARY: Although there has been progress in understanding, diagnosing and treating RLS, it remains an underdiagnosed and undertreated condition severely impairing functioning of patients with moderate-to-severe disease. Much work is needed to improve on current, as well as other novel therapies.
Authors: Wayne A Hening; Richard P Allen; Mystinna Washburn; Suzanne R Lesage; Christopher J Earley Journal: Sleep Med Date: 2009-01-29 Impact factor: 3.492
Authors: Richard P Allen; Brendan J Burchell; Ben MacDonald; Wayne A Hening; Christopher J Earley Journal: Sleep Med Date: 2009-02-04 Impact factor: 3.492
Authors: Birgit Högl; Diego García-Borreguero; Ralf Kohnen; Luigi Ferini-Strambi; Georgios Hadjigeorgiou; Magdolna Hornyak; Al de Weerd; Svenja Happe; Karin Stiasny-Kolster; Viola Gschliesser; Renata Egatz; Birgit Frauscher; Heike Benes; Claudia Trenkwalder; Wayne A Hening; Richard P Allen Journal: J Neurol Date: 2009-09-11 Impact factor: 4.849
Authors: Marco Luigetti; Alessandra Del Grande; Elisa Testani; Giulia Bisogni; Anna Losurdo; Nadia Mariagrazia Giannantoni; Salvatore Mazza; Mario Sabatelli; Giacomo Della Marca Journal: J Clin Sleep Med Date: 2013-09-15 Impact factor: 4.062
Authors: Stylianos Kosmidis; Jose A Botella; Konstantinos Mandilaras; Stephan Schneuwly; Efthimios M C Skoulakis; Tracey A Rouault; Fanis Missirlis Journal: Neurobiol Dis Date: 2011-04-01 Impact factor: 5.996